These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38318699)

  • 1. Written language achievement in children and adolescents with neurofibromatosis type 1 and Plexiform Neurofibromas.
    Siegel A; Toledo-Tamula MA; Martin S; Gillespie A; Goodwin A; Widemann B; Wolters PL
    Child Neuropsychol; 2024 Oct; 30(7):1095-1115. PubMed ID: 38318699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of cognitive development in children with neurofibromatosis type 1 and plexiform neurofibromas.
    Hou Y; Allen T; Wolters PL; Toledo-Tamula MA; Martin S; Baldwin A; Reda S; Gillespie A; Goodwin A; Widemann BC
    Dev Med Child Neurol; 2020 Aug; 62(8):977-984. PubMed ID: 32052421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal association between executive function and academic achievement in children with neurofibromatosis type 1 and plexiform neurofibromas.
    Hou Y; Wu X; Allen T; Toledo-Tamula MA; Martin S; Gillespie A; Goodwin A; Widemann BC; Wolters PL
    J Int Neuropsychol Soc; 2023 Nov; 29(9):839-849. PubMed ID: 36750981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Verbal learning and memory in youth with neurofibromatosis type 1 and plexiform neurofibromas: Relationships with disease severity.
    Loucas C; Wolters P; Toledo-Tamula MA; Rhodes A; Baldwin A; Goodwin A; Widemann B; Martin S
    Eur J Paediatr Neurol; 2022 May; 38():7-12. PubMed ID: 35334353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Underlying mechanisms of writing difficulties among children with neurofibromatosis type 1.
    Gilboa Y; Josman N; Fattal-Valevski A; Toledano-Alhadef H; Rosenblum S
    Res Dev Disabil; 2014 Jun; 35(6):1310-6. PubMed ID: 24691356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life.
    Wolters PL; Burns KM; Martin S; Baldwin A; Dombi E; Toledo-Tamula MA; Dudley WN; Gillespie A; Widemann BC
    Am J Med Genet A; 2015 Sep; 167A(9):2103-13. PubMed ID: 25976979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The handwriting performance of children with NF1.
    Gilboa Y; Josman N; Fattal-Valevski A; Toledano-Alhadef H; Rosenblum S
    Res Dev Disabil; 2010; 31(4):929-35. PubMed ID: 20392595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Visual outcomes in children with neurofibromatosis type 1 and orbitotemporal plexiform neurofibromas.
    Avery RA; Dombi E; Hutcheson KA; Acosta MT; Baldwin AM; Madigan WP; Gillespie A; Fitzgibbon EJ; Packer RJ; Widemann BC
    Am J Ophthalmol; 2013 Jun; 155(6):1089-1094.e1. PubMed ID: 23453281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient Reported Outcomes Measurement Information System and Quality of Life in Neurological Disorders Measurement System to Evaluate Quality of Life for Children and Adolescents with Neurofibromatosis Type 1 Associated Plexiform Neurofibroma.
    Lai JS; Jensen SE; Charrow J; Listernick R
    J Pediatr; 2019 Mar; 206():190-196. PubMed ID: 30413310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lifespan Development: Symptoms Experienced by Individuals with Neurofibromatosis Type 1 Associated Plexiform Neurofibromas from Childhood into Adulthood.
    Jensen SE; Patel ZS; Listernick R; Charrow J; Lai JS
    J Clin Psychol Med Settings; 2019 Sep; 26(3):259-270. PubMed ID: 30298332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features and disease severity in patients with mosaic neurofibromatosis type 1: a single-center study and literature review.
    Ejerskov C; Raundahl M; Gregersen PA; Handrup MM
    Orphanet J Rare Dis; 2021 Apr; 16(1):180. PubMed ID: 33853649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT.
    Gross AM; Achée C; Hart SE; Brewer L; Baldwin A; Wolters PL; Widemann BC;
    Future Oncol; 2024 May; 20(14):877-890. PubMed ID: 38869947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perceived transition readiness among adolescents and young adults with neurofibromatosis type 1 and plexiform neurofibromas: a cross-sectional descriptive study.
    Siegel A; Lockridge R; Struemph KL; Toledo-Tamula MA; Little P; Wolters PL; Dufek A; Tibery C; Baker M; Wideman BC; Martin S
    J Pediatr Psychol; 2024 Jun; 49(6):383-391. PubMed ID: 38366576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between benign and malignant peripheral nerve sheath tumors in NF1.
    Tucker T; Wolkenstein P; Revuz J; Zeller J; Friedman JM
    Neurology; 2005 Jul; 65(2):205-11. PubMed ID: 16043787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Social-emotional functioning of children and adolescents with neurofibromatosis type 1 and plexiform neurofibromas: relationships with cognitive, disease, and environmental variables.
    Martin S; Wolters P; Baldwin A; Gillespie A; Dombi E; Walker K; Widemann B
    J Pediatr Psychol; 2012 Aug; 37(7):713-24. PubMed ID: 22353803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.
    Robertson KA; Nalepa G; Yang FC; Bowers DC; Ho CY; Hutchins GD; Croop JM; Vik TA; Denne SC; Parada LF; Hingtgen CM; Walsh LE; Yu M; Pradhan KR; Edwards-Brown MK; Cohen MD; Fletcher JW; Travers JB; Staser KW; Lee MW; Sherman MR; Davis CJ; Miller LC; Ingram DA; Clapp DW
    Lancet Oncol; 2012 Dec; 13(12):1218-24. PubMed ID: 23099009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinic-based study of plexiform neurofibromas in neurofibromatosis 1.
    Waggoner DJ; Towbin J; Gottesman G; Gutmann DH
    Am J Med Genet; 2000 May; 92(2):132-5. PubMed ID: 10797438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1.
    Hyman SL; Shores A; North KN
    Neurology; 2005 Oct; 65(7):1037-44. PubMed ID: 16217056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is a plexiform neurofibroma pathognomonic of neurofibromatosis type I?
    Lin V; Daniel S; Forte V
    Laryngoscope; 2004 Aug; 114(8):1410-4. PubMed ID: 15280718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of nonverbal tests to screen for writing dysfluency in school-age children.
    Williams J; Zolten AJ; Rickert VI; Spence GT; Ashcraft EW
    Percept Mot Skills; 1993 Jun; 76(3 Pt 1):803-9. PubMed ID: 8321590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.